Abstract

The latest corona-virus disease (nCOVID-19) which originated in Wuhan, China, and since then has been spreading around the world is a dangerous strain of corona-virus which is a highly communicable and morbific viral infection confirmed to cause by severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2).Similarity index analysis in our study revealed that SARS-CoV-2 is related to SARS-CoV that had earlier emerged in 2002-03. The rapid transmission rates among humans and the severity of this new strain of CoV have made it a major concern worldwide. To date, the world is still lacking to approve clinically effective drugs or vaccines against COVID-19. Though clinical trials for some antiviral drugs have been tested to treat/prevent COVID-19, results are not satisfactory. As part of our response to the ongoing COVID-19 pandemic across the world, we in our current review have summarized and comparatively analyzed the sequence similarity of SARS-CoV-2 and previously identified other strains i.e. SARS-CoV(2002-03) and MERS-CoV (2012-14). We have also discussed the new potential approaches that could be effective for treating the symptoms related to nCOVID-19 to cope with this viral outbreak across the globe.

Keywords: COVID-19; SARS; MERS; Pathogenesis; Symptoms; Treatment Approaches

References

1. Rothan HA and Byrareddy SN. “The epidemiology and pathogenesis of corona-virus disease (COVID-19) outbreak”. Journal of Autoimmunity 109 (2020): 102433.
2. “Corona-virus disease”. World Health Organization 2019 (2020): 2633.
3. Lu R., et al. “Genomic characterisation and epidemiology of 2019 novel corona-virus: implications for virus origins and receptor binding”. Lancet10224 (2020): 565-574.
4. Chafekar A and Fielding BC. “MERS-CoV: Understanding the latest human corona-virus threat”. Viruses 2 (2018): 93.
5. Sigrist CJ., et al. “A potential role for integrins in host cell entry by SARS-CoV-2”. Antiviral Research 177 (2020): 104759.
6. Guo J., et al. “Corona-virus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Corona-virus 2 Infection”. Journal of the American Heart Association 7 (2020): e016219.
7. Centres for Disease Control and Prevention. 2019 Novel Corona-virus (2020).
8. Hui DS., et al. “SARS: clinical features and diagnosis”. (2003): 20-24.
9. Cheng H., et al. “Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19”. Journal of Medical Virology7 (2020): 726-730.
10. Belouzard S., et al. “Mechanisms of corona-virus cell entry mediated by the viral spike protein”. Viruses 6 (2012): 1011-1033.
11. Jose RJ and Manuel A. “COVID-19 cytokine storm: the interplay between inflammation and coagulation”. Lancet Respiratory Medicine (2019): 2019-2020.
12. Ye Q., et al. “Cytokine Storm in COVID-19 and Treatment”. Journal of Infection (2020).
13. Wang W., et al. “Updated understanding of the outbreak of 2019 novel corona-virus (2019-nCoV) in Wuhan, China”. Journal of Medical Virology4 (2020): 441-447.
14. White M. “SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19”. Gut 69 (2020): 2-3.
15. “Ministry of Health and Family Welfare” (2020).
16. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel corona-virus (2019-nCoV) in vitro”. Cell Research3 (2020): 269-271.
17. Lancet IT and Wang Y. “Remdesivir for COVID-19 : challenges of underpowered studies”. Lancet 20 (2020): 31022-31023.
18. Ekins S and Madrid PB. “Tilorone, a broad-spectrum antiviral for emerging viruses”. Antimicrobe Agents and Chemotherapy5 (2020): 1-7.
19. Duan K., et al. “Effectiveness of convalescent plasma therapy in severe COVID-19 patients”. PNAS (2020): 1-7.
20. , et al. “Therapeutic options for the treatment of 2019 ‑ novel corona-virus : An evidence based approach”. Indian Journal of Pharmacology 52.1 (2020): 1-5.
21. Chen W. “The SARS-CoV-2 Vaccine Pipeline: an Overview”. Current Tropical Medicine Reports (2020): 1-4.
22. Glowacka I., et al. “Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Corona-virus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response”. Journal of Virology9 (2011): 4122-4134.
23. Uno Y. “Camostat mesilate therapy for COVID-19”. Internal Emergency Medicine (2020): 10-11.
24. Tellis MB., et al. “Discovery of Potential Multi-Target-Directed Ligands by Targeting Host-Specific SARS-CoV-2 Structurally Conserved Main Protease”. Journal of Biomolecular Structure and Dynamics (2020): 1-16.
25. Ace H., et al. “Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Article Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using”. Cell (2020): 1-9.
26. Huang J., et al. “Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase , Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19”. Journal of Clinical Medicine 2 (2020): 1-23.
27. Gao J and Hu S. “Update on use of chloroquine/hydroxychloroquine to treat corona-virus disease 2019 (COVID-19)”. Bioscience in Trends2 (2020): 156-158.
28. Stower H. “Lopinavir-ritonavir in severe COVID-19”. Nature Medicine4 (2020): 465.
29. Branchett WJ. “Regulatory cytokine function in the respiratory tract”. Mucosal Immunology (2019).
30. Stebbing J., et al. “COVID-19 : combining antiviral and anti-inflammatory treatments”. Lancet Infection Disease19 (2020): 2019-2020.
31. Centers for Disease Control and Prevention. 2019 Novel Corona-virus (2020).
32. World Health Organization. “Novel Corona-virus (2019-nCoV) advice for the public” (2020).

Citation

Citation: Manik Ghosh., et al. “A Brief Understanding of COVID-19: Pathogenesis, Symptoms and Possible Treatment Approaches”. Acta Scientific Pharmaceutical Sciences 5.1 (2021): 70-79.

Copyright

Copyright: © 2021 Manik Ghosh., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.